PEG-MGF and IGF-1 LR3 are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two branches of the IGF-1 axis
Insulin-like growth factor 1 does not act as a single molecule so much as a family of signals. The gene is alternatively spliced, its output is buffered by binding proteins, and the biology changes completely depending on whether the signal is local and brief or systemic and sustained. PEG-MGF and IGF-1 LR3 sit on opposite ends of that spectrum. Both trace back to IGF-1, yet they were designed — and are studied — to answer different questions. PEG-MGF probes the early, mechano-responsive repair signal; IGF-1 LR3 probes sustained receptor activation. Put them side by side and the contrast is a clean lesson in how the same axis can be pulled in two directions.
| PEG-MGF | IGF-1 LR3 | |
|---|---|---|
| Class / peptide type | PEGylated IGF-1 E-domain peptide (splice variant, IGF-1Ec) | Long-acting IGF-1 analogue (Long Arg3 IGF-1) |
| Primary target | Satellite-cell pool via an uncharacterised receptor, distinct from IGF-1R | IGF-1 receptor (IGF-1R) → PI3K/Akt/mTOR & Ras/MAPK |
| Structure / MW note | Synthetic 24-aa E-domain peptide + PEG · ~5000 Da | 83 aa · Arg3 substitution + 13-aa N-terminal extension · 9111 Da |
| Half-life / duration | ~48–72 h PEGylated (native MGF ~7 min) | ~20–30 h (native IGF-1 ~6 h) |
| Main research focus | Satellite-cell activation, local muscle repair, mechanical loading | IGF-1R pharmacology, muscle/bone/metabolic biology, cell-culture tool |
| Regulatory status | Unregulated research compound · WADA-prohibited | Unregulated research compound · WADA-prohibited |
PEG-MGF: the local repair signal
Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene, produced in skeletal muscle in response to mechanical loading and tissue damage. Unlike the systemic IGF-1Ea isoform that circulates in plasma, MGF — IGF-1Ec in humans — acts locally and transiently. Its distinctive feature is a unique 24-amino-acid C-terminal "E-domain" peptide, and research has established that this fragment, independent of the IGF-1 mature sequence, carries the functionally interesting activity: it signals through a pathway that appears separate from the IGF-1 receptor and has not yet been fully characterised.
The documented biological role is activation and proliferation of muscle satellite cells — the progenitor pool responsible for repair after damage. MGF appears to mobilise that pool in the early phase of remodelling, before the slower systemic IGF-1Ea isoform drives the subsequent hypertrophy. Native MGF has a half-life measured in minutes, which makes systematic dose-response work impractical outside local-injection protocols. PEG-MGF solves that: conjugating the E-domain peptide to polyethylene glycol extends plasma half-life to roughly 48–72 hours, turning a fleeting local signal into a tractable research probe. That is the compound's defining trait — a pulsatile, repair-oriented signal made durable enough to study. Researchers sourcing material can buy PEG-MGF UK at ≥99% purity with a COA, and the full mechanistic profile lives on our PEG-MGF knowledgebase page.
IGF-1 LR3: sustained systemic action
IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) takes the opposite approach. It is a modified human IGF-1 analogue engineered with two structural changes: an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. Both modifications reduce affinity for the IGF-binding proteins (IGFBP-1 through IGFBP-6) that normally sequester the vast majority of circulating IGF-1. The result is a substantially longer half-life — around 20–30 hours versus roughly 6 for native IGF-1 — and an approximately three-fold increase in potency at the IGF-1 receptor.
Mechanistically, IGF-1 LR3 binds and activates IGF-1R directly, triggering the PI3K/Akt/mTOR and Ras/MAPK cascades that sit at the centre of mammalian anabolic and mitogenic signalling. Because IGFBPs in culture media bind native IGF-1 within minutes, the LR3 variant has become the de-facto standard reagent for IGF-1R activation in cell-culture research, holding receptor-activating concentrations across the length of a typical assay. Its research reach extends well beyond muscle — into bone formation, glucose metabolism, neuronal survival and even industrial bioprocessing in CHO-cell biologics production. Where PEG-MGF is narrow and local, IGF-1 LR3 is broad and systemic. Material is available to buy IGF-1 LR3 UK, and the IGF-1 LR3 knowledgebase page covers the full pathway detail.
What the differences mean in a research context
The cleanest way to hold these two apart is by where and how long each acts. PEG-MGF models a local, pulsatile repair trigger: an E-domain signal aimed at the satellite-cell pool, working through a receptor that is not the IGF-1 receptor and remains an open question in the literature. IGF-1 LR3 models sustained systemic IGF-1 action: direct, high-affinity activation of IGF-1R with the binding-protein interference engineered out, so the receptor stays switched on across an assay.
That distinction shapes what each is useful for. If the research question is about the early phase of muscle repair — how the satellite pool is mobilised after mechanical damage — PEG-MGF is the more relevant probe, and its PEGylation exists precisely to make that transient signal measurable. If the question is about IGF-1 receptor pharmacology, downstream anabolic signalling, or any of the broader muscle, bone, metabolic and neuronal lines that hang off IGF-1R, then IGF-1 LR3's stability and IGFBP resistance make it the reagent of choice. They are not really substitutes for one another; they interrogate different points in the same axis. It is also worth noting the shared caveat: both are unregulated research compounds, neither is approved by the MHRA or FDA, and both are WADA-prohibited in competitive sport.
The two also differ in structural scale, which reinforces the point. PEG-MGF is a small E-domain fragment dressed in PEG at around 5000 Da; IGF-1 LR3 is a full 83-amino-acid analogue at 9111 Da that reproduces the entire IGF-1 signalling molecule. One is a targeted local cue, the other a durable systemic key for the receptor lock.
The bottom line
PEG-MGF and IGF-1 LR3 both descend from IGF-1, but they answer opposite questions: a local, pulsatile satellite-cell repair signal versus sustained systemic IGF-1 receptor action. Choose PEG-MGF to study the early mechano-responsive repair phase; choose IGF-1 LR3 for durable IGF-1R activation across muscle, bone and metabolic research. For research-grade material, see our dedicated pages to buy PEG-MGF UK and buy IGF-1 LR3 UK, each ≥99% purity with a COA.